StockData
Kailera Therapeutics, Inc. logo

Kailera Therapeutics, Inc. (KLRA) stock

KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$12.20−0.37 (-2.94%)

Close on Nov 17, 2026Market cap $1.58BP/E –Yield –

Kailera Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$84.67M+333.7%
Q2 FY2026Jun 30, 2026$101.06M+897.6%
Q1 FY2026Mar 31, 2026$70.87M–
Q3 FY2025Sep 30, 2025$26.99M–
Q2 FY2025Jun 30, 2025$19.52M–
Q1 FY2025Mar 31, 2025$10.13M–

More Kailera Therapeutics figures

See a number that looks wrong?